Walpole
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 23 / 27.0 / 85.3 / (54.0-127.9) / Male / 24 / 17.1 / 140.5 / (90.0-209.0)
Female / 9 / 9.7 / 92.5 / (42.2-175.6) / Female / 16 / 12.6 / 126.8 / (72.4-206.0)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 5.3 / nc / (nc-nc) / Male / 1 / 4.3 / nc / (nc-nc)
Female / 5 / 4.1 / 123.4 / (39.8-288.1) / Female / 5 / 3.2 / 157.5 / (50.7-367.5)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.8 / nc / (nc-nc) / Male / 15 / 14.9 / 100.6 / (56.3-165.9)
Female / 112 / 94.9 / 118.1 / (97.2-142.1) / Female / 9 / 12.2 / 73.7 / (33.6-139.9)
Cervix Uteri / Oral Cavity & Pharynx
Male / 10 / 10.4 / 96.6 / (46.3-177.7)
Female / 5 / 3.8 / 132.5 / (42.7-309.1) / Female / 1 / 4.6 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 29 / 34.2 / 84.8 / (56.8-121.8)
Female / 28 / 32.8 / 85.3 / (56.6-123.2) / Female / 12 / 9.2 / 130.5 / (67.3-227.9)
Esophagus / Pancreas
Male / 5 / 7.0 / 71.2 / (22.9-166.2) / Male / 9 / 8.5 / 106.2 / (48.5-201.6)
Female / 0 / 1.9 / nc / (nc-nc) / Female / 4 / 8.7 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 2.3 / nc / (nc-nc) / Male / 94 / 98.9 / 95.1 / (76.8-116.4)
Female / 1 / 1.6 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 26 / 13.9 / 186.6 / (121.9-273.4) / Male / 7 / 6.5 / 108.2 / (43.3-222.9)
Female / 7 / 7.8 / 89.7 / (36.0-184.9) / Female / 3 / 3.7 / nc / (nc-nc)
Larynx / Testis
Male / 4 / 4.0 / nc / (nc-nc) / Male / 6 / 3.6 / 167.9 / (61.3-365.4)
Female / 0 / 1.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 5 / 9.5 / 52.9 / (17.0-123.4) / Male / 6 / 5.2 / 116.1 / (42.4-252.7)
Female / 4 / 6.9 / nc / (nc-nc) / Female / 20 / 15.0 / 133.7 / (81.6-206.4)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 4 / 7.1 / nc / (nc-nc)
Female / 2 / 2.4 / nc / (nc-nc) / Female / 25 / 21.3 / 117.6 / (76.1-173.6)
Lung and Bronchus / All Sites / Types
Male / 51 / 49.2 / 103.6 / (77.1-136.2) / Male / 346 / 356.9 / 96.9 / (87.0-107.7)
Female / 52 / 47.2 / 110.2 / (82.3-144.5) / Female / 341 / 331.5 / 102.9 / (92.2-114.4)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
316
Waltham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 52 / 60.0 / 86.7 / (64.7-113.7) / Male / 32 / 38.6 / 82.9 / (56.7-117.0)
Female / 23 / 23.4 / 98.1 / (62.2-147.3) / Female / 28 / 32.0 / 87.5 / (58.1-126.5)
Brain and Other Nervous System / Multiple Myeloma
Male / 7 / 12.0 / 58.1 / (23.3-119.7) / Male / 13 / 9.5 / 136.9 / (72.8-234.0)
Female / 10 / 10.0 / 100.3 / (48.0-184.4) / Female / 5 / 7.6 / 65.6 / (21.1-153.0)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 1.7 / nc / (nc-nc) / Male / 38 / 33.7 / 112.9 / (79.9-154.9)
Female / 228 / 223.1 / 102.2 / (89.4-116.4) / Female / 27 / 29.7 / 90.8 / (59.8-132.1)
Cervix Uteri / Oral Cavity & Pharynx
Male / 31 / 22.8 / 136.2 / (92.5-193.3)
Female / 8 / 9.5 / 84.3 / (36.3-166.2) / Female / 11 / 11.2 / 98.5 / (49.1-176.3)
Colon / Rectum / Ovary
Male / 54 / 75.7 / 71.4 / (53.6-93.1)
Female / 85 / 78.6 / 108.2 / (86.4-133.8) / Female / 27 / 22.1 / 121.9 / (80.3-177.4)
Esophagus / Pancreas
Male / 10 / 15.5 / 64.3 / (30.8-118.3) / Male / 22 / 18.8 / 117.3 / (73.5-177.6)
Female / 7 / 4.6 / 153.7 / (61.6-316.7) / Female / 26 / 20.8 / 124.8 / (81.5-182.8)
Hodgkin Lymphoma / Prostate
Male / 3 / 6.5 / nc / (nc-nc) / Male / 206 / 218.6 / 94.2 / (81.8-108.0)
Female / 6 / 4.9 / 123.0 / (44.9-267.8)
Kidney & Renal Pelvis / Stomach
Male / 26 / 30.8 / 84.5 / (55.2-123.9) / Male / 15 / 14.4 / 104.4 / (58.4-172.3)
Female / 15 / 18.7 / 80.1 / (44.8-132.1) / Female / 8 / 8.9 / 89.9 / (38.7-177.2)
Larynx / Testis
Male / 8 / 8.9 / 90.0 / (38.7-177.3) / Male / 12 / 10.9 / 109.9 / (56.7-192.0)
Female / 2 / 2.6 / nc / (nc-nc)
Leukemia / Thyroid
Male / 11 / 21.3 / 51.6 / (25.7-92.4) / Male / 12 / 12.2 / 98.7 / (50.9-172.4)
Female / 21 / 16.6 / 126.6 / (78.4-193.6) / Female / 32 / 38.6 / 82.8 / (56.7-117.0)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 13 / 15.6 / 83.3 / (44.3-142.5)
Female / 6 / 5.7 / 105.2 / (38.4-229.1) / Female / 41 / 50.3 / 81.5 / (58.5-110.5)
Lung and Bronchus / All Sites / Types
Male / 115 / 109.4 / 105.1 / (86.8-126.2) / Male / 730 / 798.8 / 91.4 / (84.9-98.3)
Female / 96 / 114.1 / 84.2 / (68.2-102.8) / Female / 774 / 797.9 / 97.0 / (90.3-104.1)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
317
Ware
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 10 / 11.7 / 85.3 / (40.8-156.9) / Male / 6 / 7.3 / 82.6 / (30.2-179.7)
Female / 3 / 4.7 / nc / (nc-nc) / Female / 6 / 5.8 / 102.7 / (37.5-223.6)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 2.2 / nc / (nc-nc) / Male / 0 / 1.9 / nc / (nc-nc)
Female / 2 / 1.9 / nc / (nc-nc) / Female / 0 / 1.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.3 / nc / (nc-nc) / Male / 4 / 6.4 / nc / (nc-nc)
Female / 26 / 42.4 / 61.3 / (40.0-89.8) / Female / 8 / 5.8 / 136.9 / (58.9-269.7)
Cervix Uteri / Oral Cavity & Pharynx
Male / 7 / 4.4 / 158.6 / (63.5-326.8)
Female / 2 / 1.7 / nc / (nc-nc) / Female / 2 / 2.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 16 / 14.7 / 108.5 / (62.0-176.2)
Female / 8 / 16.0 / 50.1 / (21.6-98.7) / Female / 6 / 4.2 / 142.1 / (51.9-309.3)
Esophagus / Pancreas
Male / 2 / 3.0 / nc / (nc-nc) / Male / 3 / 3.7 / nc / (nc-nc)
Female / 0 / 0.9 / nc / (nc-nc) / Female / 1 / 4.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 1.0 / nc / (nc-nc) / Male / 31 / 42.9 / 72.2 / (49.1-102.5)
Female / 1 / 0.8 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 4 / 5.9 / nc / (nc-nc) / Male / 3 / 2.8 / nc / (nc-nc)
Female / 2 / 3.6 / nc / (nc-nc) / Female / 1 / 1.8 / nc / (nc-nc)
Larynx / Testis
Male / 4 / 1.7 / nc / (nc-nc) / Male / 3 / 1.5 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 4.0 / nc / (nc-nc) / Male / 1 / 2.1 / nc / (nc-nc)
Female / 1 / 3.2 / nc / (nc-nc) / Female / 4 / 6.6 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 3.1 / nc / (nc-nc)
Female / 1 / 1.1 / nc / (nc-nc) / Female / 9 / 9.5 / 94.4 / (43.1-179.3)
Lung and Bronchus / All Sites / Types
Male / 20 / 21.3 / 93.9 / (57.3-145.0) / Male / 132 / 153.9 / 85.8 / (71.8-101.7)
Female / 21 / 22.3 / 94.2 / (58.3-143.9) / Female / 116 / 153.8 / 75.4 / (62.3-90.5)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
318
Wareham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 35 / 27.2 / 128.9 / (89.8-179.3) / Male / 8 / 16.6 / 48.2 / (20.7-94.9)
Female / 11 / 10.0 / 110.3 / (55.0-197.4) / Female / 6 / 12.7 / 47.1 / (17.2-102.6)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 4.9 / nc / (nc-nc) / Male / 4 / 4.3 / nc / (nc-nc)
Female / 3 / 4.1 / nc / (nc-nc) / Female / 2 / 3.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.8 / nc / (nc-nc) / Male / 12 / 14.4 / 83.3 / (43.0-145.6)
Female / 94 / 95.8 / 98.2 / (79.3-120.1) / Female / 8 / 12.5 / 64.1 / (27.6-126.3)
Cervix Uteri / Oral Cavity & Pharynx
Male / 12 / 10.1 / 118.9 / (61.4-207.8)
Female / 1 / 3.7 / nc / (nc-nc) / Female / 6 / 4.7 / 126.8 / (46.3-276.0)
Colon / Rectum / Ovary
Male / 54 / 33.9 / 159.2 / (119.6-207.7)
Female / 37 / 32.7 / 113.3 / (79.7-156.1) / Female / 11 / 9.4 / 117.3 / (58.5-209.9)
Esophagus / Pancreas
Male / 13 / 7.1 / 183.1 / (97.4-313.2) / Male / 12 / 8.5 / 141.2 / (72.9-246.7)
Female / 0 / 2.0 / nc / (nc-nc) / Female / 15 / 8.8 / 170.0 / (95.1-280.4)
Hodgkin Lymphoma / Prostate
Male / 3 / 2.0 / nc / (nc-nc) / Male / 97 / 103.1 / 94.1 / (76.3-114.8)
Female / 2 / 1.6 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 19 / 13.7 / 139.1 / (83.7-217.3) / Male / 4 / 6.4 / nc / (nc-nc)
Female / 6 / 8.0 / 74.6 / (27.2-162.3) / Female / 2 / 3.7 / nc / (nc-nc)
Larynx / Testis
Male / 8 / 4.1 / 195.7 / (84.2-385.5) / Male / 2 / 2.9 / nc / (nc-nc)
Female / 3 / 1.1 / nc / (nc-nc)
Leukemia / Thyroid
Male / 16 / 9.2 / 174.8 / (99.9-283.9) / Male / 1 / 4.7 / nc / (nc-nc)
Female / 4 / 6.8 / nc / (nc-nc) / Female / 12 / 14.9 / 80.4 / (41.5-140.4)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 11 / 7.0 / 157.3 / (78.4-281.5)
Female / 5 / 2.4 / 207.9 / (67.0-485.1) / Female / 22 / 22.2 / 99.3 / (62.2-150.4)
Lung and Bronchus / All Sites / Types
Male / 67 / 50.3 / 133.3 / (103.3-169.3) / Male / 415 / 358.0 / 115.9 / (105.0-127.6)
Female / 62 / 49.7 / 124.7 / (95.6-159.9) / Female / 345 / 337.0 / 102.4 / (91.9-113.8)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
319
Warren
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 5 / 5.5 / 90.9 / (29.3-212.2) / Male / 2 / 3.5 / nc / (nc-nc)
Female / 1 / 1.8 / nc / (nc-nc) / Female / 4 / 2.6 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 1 / 1.1 / nc / (nc-nc) / Male / 0 / 0.9 / nc / (nc-nc)
Female / 0 / 0.8 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 3.1 / nc / (nc-nc)
Female / 25 / 18.9 / 132.6 / (85.8-195.8) / Female / 3 / 2.4 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 2.2 / nc / (nc-nc)
Female / 0 / 0.8 / nc / (nc-nc) / Female / 1 / 0.9 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 6 / 7.0 / 85.4 / (31.2-185.9)
Female / 5 / 6.1 / 81.7 / (26.3-190.7) / Female / 1 / 1.8 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 1.5 / nc / (nc-nc) / Male / 4 / 1.7 / nc / (nc-nc)
Female / 2 / 0.4 / nc / (nc-nc) / Female / 2 / 1.6 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.5 / nc / (nc-nc) / Male / 13 / 21.3 / 61.0 / (32.4-104.3)
Female / 1 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 2 / 2.9 / nc / (nc-nc) / Male / 1 / 1.3 / nc / (nc-nc)
Female / 2 / 1.5 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 0.9 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 1.9 / nc / (nc-nc) / Male / 1 / 1.1 / nc / (nc-nc)
Female / 3 / 1.3 / nc / (nc-nc) / Female / 5 / 3.3 / 153.7 / (49.5-358.7)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 1 / 1.5 / nc / (nc-nc)
Female / 0 / 0.5 / nc / (nc-nc) / Female / 4 / 4.3 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 10 / 10.2 / 98.2 / (47.0-180.7) / Male / 52 / 74.5 / 69.8 / (52.1-91.5)
Female / 16 / 9.1 / 175.9 / (100.5-285.7) / Female / 80 / 65.1 / 123.0 / (97.5-153.0)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
320
Warwick
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 1 / 0.8 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.5 / nc / (nc-nc)
Female / 1 / 3.0 / nc / (nc-nc) / Female / 1 / 0.3 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 1 / 1.1 / nc / (nc-nc)
Female / 0 / 0.8 / nc / (nc-nc) / Female / 1 / 0.3 / nc / (nc-nc)
Esophagus / Pancreas
Male / 1 / 0.2 / nc / (nc-nc) / Male / 1 / 0.3 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 5 / 3.3 / 152.0 / (49.0-354.8)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.5 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 2 / 0.5 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 2 / 0.7 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 1 / 1.5 / nc / (nc-nc) / Male / 10 / 11.5 / 87.3 / (41.8-160.6)
Female / 0 / 1.3 / nc / (nc-nc) / Female / 7 / 9.8 / 71.4 / (28.6-147.1)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
321
Washington
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 0 / 0.6 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 1 / 0.3 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.3 / nc / (nc-nc)
Female / 1 / 2.1 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 2 / 0.8 / nc / (nc-nc)
Female / 1 / 0.6 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.2 / nc / (nc-nc) / Male / 1 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 1 / 0.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 4 / 2.4 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 0.3 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.1 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.1 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.4 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 1 / 1.1 / nc / (nc-nc) / Male / 8 / 8.3 / 96.3 / (41.5-189.8)
Female / 0 / 0.9 / nc / (nc-nc) / Female / 5 / 6.7 / 74.6 / (24.0-174.0)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
322
Watertown
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 47 / 38.0 / 123.5 / (90.8-164.3) / Male / 15 / 23.1 / 65.1 / (36.4-107.3)
Female / 16 / 16.6 / 96.5 / (55.1-156.8) / Female / 21 / 20.7 / 101.2 / (62.6-154.8)
Brain and Other Nervous System / Multiple Myeloma
Male / 7 / 6.9 / 101.6 / (40.7-209.3) / Male / 5 / 5.9 / 85.4 / (27.5-199.2)
Female / 8 / 6.4 / 125.1 / (53.9-246.5) / Female / 2 / 5.3 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 1.0 / nc / (nc-nc) / Male / 11 / 20.2 / 54.5 / (27.2-97.6)
Female / 124 / 146.1 / 84.9 / (70.6-101.2) / Female / 23 / 20.4 / 112.7 / (71.4-169.1)
Cervix Uteri / Oral Cavity & Pharynx
Male / 9 / 13.1 / 68.7 / (31.4-130.4)
Female / 6 / 6.0 / 99.5 / (36.3-216.5) / Female / 9 / 7.5 / 120.5 / (55.0-228.8)
Colon / Rectum / Ovary
Male / 35 / 46.7 / 74.9 / (52.2-104.2)
Female / 47 / 55.8 / 84.3 / (61.9-112.0) / Female / 16 / 14.6 / 109.8 / (62.7-178.3)
Esophagus / Pancreas
Male / 6 / 9.4 / 64.2 / (23.4-139.7) / Male / 18 / 11.6 / 154.5 / (91.5-244.2)
Female / 5 / 3.2 / 154.4 / (49.8-360.3) / Female / 21 / 14.8 / 141.5 / (87.6-216.3)
Hodgkin Lymphoma / Prostate
Male / 6 / 3.4 / 177.6 / (64.8-386.5) / Male / 116 / 130.5 / 88.9 / (73.5-106.6)
Female / 3 / 2.8 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 16 / 18.2 / 87.7 / (50.1-142.4) / Male / 8 / 9.0 / 89.0 / (38.3-175.3)
Female / 15 / 12.6 / 119.1 / (66.6-196.5) / Female / 5 / 6.4 / 78.1 / (25.2-182.3)
Larynx / Testis
Male / 6 / 5.3 / 112.8 / (41.2-245.6) / Male / 6 / 5.6 / 106.4 / (38.8-231.5)
Female / 0 / 1.7 / nc / (nc-nc)
Leukemia / Thyroid
Male / 12 / 12.8 / 93.8 / (48.4-163.9) / Male / 5 / 6.8 / 73.7 / (23.7-171.9)
Female / 8 / 11.3 / 71.0 / (30.6-139.8) / Female / 28 / 23.8 / 117.8 / (78.2-170.2)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 8 / 9.1 / 87.5 / (37.7-172.3)
Female / 3 / 4.0 / nc / (nc-nc) / Female / 33 / 32.3 / 102.0 / (70.2-143.3)
Lung and Bronchus / All Sites / Types
Male / 61 / 68.4 / 89.2 / (68.2-114.6) / Male / 427 / 483.4 / 88.3 / (80.1-97.1)
Female / 73 / 78.9 / 92.5 / (72.5-116.3) / Female / 499 / 536.5 / 93.0 / (85.0-101.5)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
323
Wayland
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 16 / 16.1 / 99.6 / (56.9-161.7) / Male / 11 / 10.1 / 108.8 / (54.2-194.6)
Female / 5 / 5.5 / 91.6 / (29.5-213.8) / Female / 11 / 7.5 / 147.3 / (73.4-263.6)
Brain and Other Nervous System / Multiple Myeloma
Male / 3 / 3.1 / nc / (nc-nc) / Male / 4 / 2.6 / nc / (nc-nc)
Female / 5 / 2.4 / 210.3 / (67.8-490.7) / Female / 0 / 1.8 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.5 / nc / (nc-nc) / Male / 15 / 8.8 / 170.4 / (95.3-281.1)
Female / 84 / 58.2 / 144.3 / (115.1-178.6) / Female / 11 / 7.0 / 157.0 / (78.3-280.9)
Cervix Uteri / Oral Cavity & Pharynx
Male / 7 / 6.4 / 110.0 / (44.1-226.6)
Female / 0 / 2.3 / nc / (nc-nc) / Female / 0 / 2.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 21 / 20.5 / 102.5 / (63.4-156.7)
Female / 18 / 18.3 / 98.3 / (58.2-155.3) / Female / 7 / 5.5 / 126.4 / (50.6-260.5)
Esophagus / Pancreas
Male / 1 / 4.3 / nc / (nc-nc) / Male / 7 / 5.1 / 137.4 / (55.0-283.0)
Female / 0 / 1.1 / nc / (nc-nc) / Female / 4 / 4.8 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 3 / 1.1 / nc / (nc-nc) / Male / 61 / 61.9 / 98.5 / (75.4-126.6)
Female / 0 / 0.9 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 6 / 8.4 / 71.1 / (26.0-154.7) / Male / 2 / 3.8 / nc / (nc-nc)
Female / 4 / 4.7 / nc / (nc-nc) / Female / 0 / 2.0 / nc / (nc-nc)
Larynx / Testis
Male / 3 / 2.5 / nc / (nc-nc) / Male / 1 / 1.6 / nc / (nc-nc)
Female / 0 / 0.7 / nc / (nc-nc)
Leukemia / Thyroid
Male / 3 / 5.6 / nc / (nc-nc) / Male / 3 / 3.0 / nc / (nc-nc)
Female / 6 / 3.9 / 154.0 / (56.2-335.2) / Female / 16 / 9.2 / 173.5 / (99.1-281.8)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 4.4 / nc / (nc-nc)
Female / 2 / 1.4 / nc / (nc-nc) / Female / 12 / 13.3 / 90.5 / (46.7-158.1)
Lung and Bronchus / All Sites / Types
Male / 23 / 29.9 / 77.0 / (48.8-115.5) / Male / 204 / 215.7 / 94.6 / (82.0-108.5)
Female / 25 / 27.4 / 91.2 / (59.0-134.7) / Female / 224 / 195.6 / 114.5 / (100.0-130.5)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
324
Webster
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 23 / 20.3 / 113.2 / (71.7-169.9) / Male / 7 / 12.4 / 56.7 / (22.7-116.8)
Female / 10 / 8.2 / 121.6 / (58.2-223.7) / Female / 2 / 10.1 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 7 / 3.7 / 186.8 / (74.8-384.9) / Male / 2 / 3.2 / nc / (nc-nc)
Female / 3 / 3.2 / nc / (nc-nc) / Female / 3 / 2.7 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.6 / nc / (nc-nc) / Male / 10 / 10.9 / 91.8 / (44.0-168.9)
Female / 74 / 72.5 / 102.1 / (80.2-128.2) / Female / 13 / 10.1 / 128.3 / (68.2-219.3)
Cervix Uteri / Oral Cavity & Pharynx
Male / 6 / 7.4 / 81.5 / (29.8-177.5)
Female / 7 / 2.9 / 245.3 / (98.3-505.5) / Female / 3 / 3.7 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 31 / 25.3 / 122.7 / (83.4-174.2)
Female / 34 / 28.1 / 120.9 / (83.7-169.0) / Female / 4 / 7.2 / nc / (nc-nc)
Esophagus / Pancreas
Male / 7 / 5.1 / 136.2 / (54.6-280.7) / Male / 10 / 6.3 / 158.7 / (76.0-291.9)
Female / 2 / 1.6 / nc / (nc-nc) / Female / 3 / 7.4 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 3 / 1.6 / nc / (nc-nc) / Male / 57 / 71.5 / 79.7 / (60.4-103.3)
Female / 0 / 1.3 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 11 / 10.0 / 109.9 / (54.8-196.7) / Male / 6 / 4.8 / 124.7 / (45.6-271.5)
Female / 9 / 6.2 / 145.5 / (66.4-276.3) / Female / 0 / 3.2 / nc / (nc-nc)
Larynx / Testis
Male / 3 / 2.9 / nc / (nc-nc) / Male / 1 / 2.5 / nc / (nc-nc)
Female / 2 / 0.8 / nc / (nc-nc)
Leukemia / Thyroid
Male / 13 / 7.0 / 186.5 / (99.2-319.0) / Male / 3 / 3.6 / nc / (nc-nc)
Female / 9 / 5.7 / 157.6 / (71.9-299.1) / Female / 10 / 11.2 / 89.2 / (42.7-164.1)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 3 / 5.1 / nc / (nc-nc)
Female / 5 / 2.0 / 251.5 / (81.0-586.9) / Female / 18 / 16.1 / 112.0 / (66.3-177.0)
Lung and Bronchus / All Sites / Types
Male / 34 / 36.5 / 93.0 / (64.4-130.0) / Male / 265 / 261.2 / 101.4 / (89.6-114.4)
Female / 37 / 38.6 / 96.0 / (67.6-132.3) / Female / 272 / 265.5 / 102.4 / (90.6-115.4)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
325
Wellesley
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 17 / 29.3 / 58.0 / (33.8-92.9) / Male / 28 / 18.2 / 153.7 / (102.1-222.1)
Female / 13 / 11.2 / 115.7 / (61.5-197.8) / Female / 19 / 15.1 / 126.0 / (75.8-196.8)
Brain and Other Nervous System / Multiple Myeloma
Male / 3 / 5.6 / nc / (nc-nc) / Male / 6 / 4.7 / 128.0 / (46.7-278.6)
Female / 1 / 4.9 / nc / (nc-nc) / Female / 4 / 3.7 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.8 / nc / (nc-nc) / Male / 18 / 15.9 / 113.0 / (66.9-178.6)
Female / 115 / 110.0 / 104.6 / (86.3-125.5) / Female / 18 / 14.3 / 125.5 / (74.3-198.3)
Cervix Uteri / Oral Cavity & Pharynx
Male / 9 / 11.3 / 79.3 / (36.2-150.6)
Female / 1 / 4.4 / nc / (nc-nc) / Female / 6 / 5.4 / 111.3 / (40.6-242.3)
Colon / Rectum / Ovary
Male / 24 / 37.2 / 64.4 / (41.3-95.9)
Female / 28 / 38.1 / 73.4 / (48.8-106.2) / Female / 11 / 10.8 / 101.5 / (50.6-181.6)
Esophagus / Pancreas
Male / 2 / 7.7 / nc / (nc-nc) / Male / 13 / 9.2 / 140.8 / (74.9-240.8)
Female / 3 / 2.2 / nc / (nc-nc) / Female / 6 / 10.1 / 59.6 / (21.8-129.7)
Hodgkin Lymphoma / Prostate
Male / 1 / 2.1 / nc / (nc-nc) / Male / 119 / 109.6 / 108.6 / (90.0-130.0)
Female / 3 / 2.3 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 13 / 15.1 / 86.2 / (45.8-147.4) / Male / 5 / 7.0 / 71.5 / (23.0-166.8)
Female / 6 / 9.1 / 66.2 / (24.2-144.1) / Female / 5 / 4.3 / 116.5 / (37.5-271.8)
Larynx / Testis
Male / 1 / 4.4 / nc / (nc-nc) / Male / 5 / 3.1 / 162.5 / (52.4-379.3)
Female / 1 / 1.3 / nc / (nc-nc)
Leukemia / Thyroid
Male / 11 / 10.2 / 107.6 / (53.6-192.5) / Male / 8 / 5.3 / 150.8 / (64.9-297.2)
Female / 9 / 8.1 / 110.6 / (50.5-210.0) / Female / 26 / 18.0 / 144.6 / (94.4-211.9)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 8 / 7.9 / 101.6 / (43.8-200.3)
Female / 4 / 2.8 / nc / (nc-nc) / Female / 25 / 24.8 / 101.0 / (65.3-149.1)
Lung and Bronchus / All Sites / Types
Male / 16 / 53.7 / 29.8 / (17.0-48.4) / Male / 338 / 388.1 / 87.1 / (78.1-96.9)
Female / 32 / 54.6 / 58.6 / (40.1-82.8) / Female / 369 / 386.8 / 95.4 / (85.9-105.6)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
326
Wellfleet
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 13 / 5.0 / 261.2 / (138.9-446.6) / Male / 3 / 2.8 / nc / (nc-nc)
Female / 1 / 1.6 / nc / (nc-nc) / Female / 6 / 2.0 / 303.6 / (110.9-660.8)
Brain and Other Nervous System / Multiple Myeloma
Male / 2 / 0.8 / nc / (nc-nc) / Male / 1 / 0.8 / nc / (nc-nc)
Female / 2 / 0.6 / nc / (nc-nc) / Female / 1 / 0.5 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 2 / 0.1 / nc / (nc-nc) / Male / 2 / 2.5 / nc / (nc-nc)
Female / 19 / 15.3 / 123.9 / (74.6-193.5) / Female / 2 / 2.0 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 0 / 1.6 / nc / (nc-nc)
Female / 1 / 0.6 / nc / (nc-nc) / Female / 2 / 0.8 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 5 / 6.1 / 82.6 / (26.6-192.8)
Female / 3 / 5.4 / nc / (nc-nc) / Female / 2 / 1.5 / nc / (nc-nc)
Esophagus / Pancreas
Male / 2 / 1.2 / nc / (nc-nc) / Male / 1 / 1.5 / nc / (nc-nc)
Female / 1 / 0.3 / nc / (nc-nc) / Female / 1 / 1.5 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.3 / nc / (nc-nc) / Male / 24 / 16.9 / 141.8 / (90.8-211.0)
Female / 0 / 0.2 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 0 / 2.3 / nc / (nc-nc) / Male / 3 / 1.2 / nc / (nc-nc)
Female / 0 / 1.3 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.7 / nc / (nc-nc) / Male / 0 / 0.4 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 1 / 1.6 / nc / (nc-nc) / Male / 0 / 0.7 / nc / (nc-nc)
Female / 2 / 1.1 / nc / (nc-nc) / Female / 1 / 2.2 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 1.2 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc) / Female / 4 / 3.5 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 5 / 8.9 / 56.2 / (18.1-131.1) / Male / 69 / 61.2 / 112.7 / (87.7-142.7)
Female / 7 / 8.2 / 85.7 / (34.3-176.6) / Female / 59 / 54.1 / 109.0 / (83.0-140.6)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
327
Wendell
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 0 / 0.9 / nc / (nc-nc) / Male / 2 / 0.7 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.5 / nc / (nc-nc)
Brain and Other Nervous System / Multiple Myeloma
Male / 0 / 0.2 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.0 / nc / (nc-nc) / Male / 0 / 0.6 / nc / (nc-nc)
Female / 5 / 3.4 / 146.9 / (47.3-342.8) / Female / 0 / 0.3 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 2 / 0.5 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 1 / 1.2 / nc / (nc-nc)
Female / 2 / 0.8 / nc / (nc-nc) / Female / 0 / 0.3 / nc / (nc-nc)
Esophagus / Pancreas
Male / 0 / 0.3 / nc / (nc-nc) / Male / 1 / 0.3 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc) / Female / 0 / 0.2 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 0.1 / nc / (nc-nc) / Male / 5 / 3.8 / 133.2 / (42.9-310.8)
Female / 0 / 0.1 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 0.5 / nc / (nc-nc) / Male / 1 / 0.2 / nc / (nc-nc)
Female / 0 / 0.2 / nc / (nc-nc) / Female / 0 / 0.1 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.2 / nc / (nc-nc) / Male / 1 / 0.2 / nc / (nc-nc)
Female / 0 / 0.0 / nc / (nc-nc)
Leukemia / Thyroid
Male / 0 / 0.4 / nc / (nc-nc) / Male / 0 / 0.2 / nc / (nc-nc)
Female / 1 / 0.2 / nc / (nc-nc) / Female / 0 / 0.7 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 0 / 0.3 / nc / (nc-nc)
Female / 0 / 0.1 / nc / (nc-nc) / Female / 1 / 0.8 / nc / (nc-nc)
Lung and Bronchus / All Sites / Types
Male / 1 / 1.6 / nc / (nc-nc) / Male / 16 / 13.0 / 122.8 / (70.1-199.4)
Female / 1 / 1.1 / nc / (nc-nc) / Female / 10 / 10.3 / 97.4 / (46.6-179.2)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
328
Wenham
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 2 / 5.1 / nc / (nc-nc) / Male / 4 / 3.0 / nc / (nc-nc)
Female / 6 / 1.8 / 341.2 / (124.6-742.7) / Female / 8 / 2.3 / 342.1 / (147.3-674.2)
Brain and Other Nervous System / Multiple Myeloma
Male / 4 / 0.9 / nc / (nc-nc) / Male / 0 / 0.8 / nc / (nc-nc)
Female / 0 / 0.8 / nc / (nc-nc) / Female / 0 / 0.6 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 0 / 0.1 / nc / (nc-nc) / Male / 1 / 2.7 / nc / (nc-nc)
Female / 19 / 16.8 / 113.2 / (68.1-176.8) / Female / 0 / 2.2 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 2 / 1.8 / nc / (nc-nc)
Female / 1 / 0.7 / nc / (nc-nc) / Female / 1 / 0.8 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 4 / 6.2 / nc / (nc-nc)
Female / 9 / 5.8 / 154.5 / (70.5-293.3) / Female / 2 / 1.7 / nc / (nc-nc)
Esophagus / Pancreas
Male / 2 / 1.3 / nc / (nc-nc) / Male / 0 / 1.6 / nc / (nc-nc)
Female / 1 / 0.3 / nc / (nc-nc) / Female / 0 / 1.6 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 1 / 0.4 / nc / (nc-nc) / Male / 20 / 17.9 / 111.8 / (68.3-172.7)
Female / 1 / 0.4 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 1 / 2.5 / nc / (nc-nc) / Male / 0 / 1.2 / nc / (nc-nc)
Female / 3 / 1.4 / nc / (nc-nc) / Female / 2 / 0.7 / nc / (nc-nc)
Larynx / Testis
Male / 0 / 0.7 / nc / (nc-nc) / Male / 0 / 0.6 / nc / (nc-nc)
Female / 1 / 0.2 / nc / (nc-nc)
Leukemia / Thyroid
Male / 2 / 1.7 / nc / (nc-nc) / Male / 3 / 0.9 / nc / (nc-nc)
Female / 3 / 1.3 / nc / (nc-nc) / Female / 3 / 2.8 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 1.3 / nc / (nc-nc)
Female / 1 / 0.4 / nc / (nc-nc) / Female / 6 / 3.7 / 160.5 / (58.6-349.2)
Lung and Bronchus / All Sites / Types
Male / 8 / 9.3 / 86.4 / (37.2-170.2) / Male / 61 / 65.1 / 93.7 / (71.7-120.3)
Female / 6 / 8.7 / 69.1 / (25.2-150.5) / Female / 78 / 59.8 / 130.5 / (103.2-162.9)
Obs = observed case count; Exp = expected case count;
SIR = standardized incidence ratio ( (Obs / Exp) X 100);
95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
Shading indicates the statistical significance of the SIR at 95% level of probability;
nc = The SIR and 95% CI were not calculated when Obs < 5;
329
West Boylston
Observed and Expected Case Counts, with Standardized Incidence Ratios, 2004-2008
Obs / Exp / SIR / 95% CI / Obs / Exp / SIR / 95% CIBladder, Urinary / Melanoma of Skin
Male / 6 / 9.0 / 66.9 / (24.4-145.7) / Male / 4 / 5.9 / nc / (nc-nc)
Female / 4 / 3.0 / nc / (nc-nc) / Female / 5 / 3.8 / 132.7 / (42.8-309.8)
Brain and Other Nervous System / Multiple Myeloma
Male / 3 / 1.8 / nc / (nc-nc) / Male / 2 / 1.4 / nc / (nc-nc)
Female / 2 / 1.2 / nc / (nc-nc) / Female / 2 / 1.0 / nc / (nc-nc)
Breast / Non-Hodgkin Lymphoma
Male / 1 / 0.2 / nc / (nc-nc) / Male / 12 / 5.1 / 234.6 / (121.1-409.8)
Female / 37 / 28.3 / 130.5 / (91.9-179.9) / Female / 1 / 3.7 / nc / (nc-nc)
Cervix Uteri / Oral Cavity & Pharynx
Male / 1 / 3.5 / nc / (nc-nc)
Female / 3 / 1.1 / nc / (nc-nc) / Female / 0 / 1.4 / nc / (nc-nc)
Colon / Rectum / Ovary
Male / 7 / 11.4 / 61.3 / (24.5-126.2)
Female / 5 / 10.2 / 49.2 / (15.9-114.9) / Female / 1 / 2.8 / nc / (nc-nc)
Esophagus / Pancreas
Male / 2 / 2.3 / nc / (nc-nc) / Male / 5 / 2.8 / 178.0 / (57.4-415.4)
Female / 0 / 0.6 / nc / (nc-nc) / Female / 1 / 2.7 / nc / (nc-nc)
Hodgkin Lymphoma / Prostate
Male / 0 / 1.0 / nc / (nc-nc) / Male / 25 / 32.0 / 78.0 / (50.5-115.2)
Female / 0 / 0.5 / nc / (nc-nc)
Kidney & Renal Pelvis / Stomach
Male / 7 / 4.7 / 150.4 / (60.3-309.9) / Male / 1 / 2.2 / nc / (nc-nc)
Female / 2 / 2.4 / nc / (nc-nc) / Female / 1 / 1.1 / nc / (nc-nc)
Larynx / Testis
Male / 1 / 1.3 / nc / (nc-nc) / Male / 0 / 1.6 / nc / (nc-nc)
Female / 0 / 0.3 / nc / (nc-nc)
Leukemia / Thyroid
Male / 3 / 3.2 / nc / (nc-nc) / Male / 4 / 1.9 / nc / (nc-nc)
Female / 4 / 2.1 / nc / (nc-nc) / Female / 2 / 4.4 / nc / (nc-nc)
Liver and Intrahepatic Bile Ducts / Uteri Corpus and Uterus, NOS
Male / 2 / 2.4 / nc / (nc-nc)
Female / 0 / 0.7 / nc / (nc-nc) / Female / 10 / 6.3 / 159.2 / (76.2-292.8)
Lung and Bronchus / All Sites / Types
Male / 14 / 16.2 / 86.2 / (47.1-144.6) / Male / 109 / 119.3 / 91.4 / (75.0-110.2)
Female / 20 / 14.5 / 137.8 / (84.2-212.9) / Female / 103 / 100.2 / 102.8 / (83.9-124.6)
Obs = observed case count; Exp = expected case count;